
MaaT Pharma Updates MaaT013 Development Plan Following Negative CHMP Opinion
MaaT Pharma Reports CHMP Maintains Negative Opinion on MaaT013 for Acute Graft-versus-Host Disease MaaT Pharma (Euronext: MAAT), a clinical-stage biotechnology company developing Microbiome Ecosystem Therapies™ (MET) designed to modulate the…












